Exelixis, Inc. (NASDAQ:EXEL) Q2 2024 Earnings Conference Call August 6, 2024 5:00 PM ET
Company Participants
Susan Hubbard - Executive Vice President, Public Affairs and Investor Relations
Michael Morrissey - President and Chief Executive Officer
Christopher Senner - Executive Vice President and Chief Financial Officer
Amy Peterson - Executive Vice President, Product Development, Medical Affairs and Chief Medical Officer
Dana Aftab - Chief Scientific Officer
P.J. Haley - Executive Vice President of Commercial
Conference Call Participants
Asthika Goonewardene - Truist
Jay Olson - Oppenheimer
Joyce Zhou - TD Cowen
Andy Hsieh - William Blair
Silvan Tuerkcan - Citizens JMP
David Lebowitz - Citi
Michael Riad - Morgan Stanley
Jason Gerberry - Bank of America
Akash Tewari - Jefferies
Alex Bullocks - Barclays
Sudan Loganathan - Stephens
Chris Shibutani - Goldman Sachs
Operator
Good day, ladies and gentlemen, and welcome to the Exelixis Second Quarter 2024 Financial Results Conference Call. My name is Tawanda and I'll be your operator for today. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to your host for today, Ms. Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations. You may begin.
Susan Hubbard
Thank you, Tawanda, and thank you all for joining us for the Exelixis second quarter 2024 financial results conference call. Joining me on today's call are Mike Morrissey, our President and CEO; Chris Senner, our Chief Financial Officer; P.J. Haley, our Executive Vice President of Commercial; Amy Peterson, our Chief Medical Officer; and Dana Aftab, our Chief Scientific Officer, who together will review our progress for the second quarter 2024 ended June 30, 2024.
During the call today, we will refer to financial measures not calculated according to generally accepted accounting principles. Please refer to today's press release, which is posted on our website for an explanation of our reasons for using such non-GAAP measures as well as tables deriving these measures from our GAAP results.
During the course of this presentation, we will be making forward-looking statements regarding future events and the future performance of the company. This includes statements about possible developments regarding discovery, product development, regulatory, commercial, financial and strategic matters. Actual events or results could, of course, differ materially.
We refer you to the documents we file from time-to-time with the SEC, which under the heading Risk Factors identify important factors that could cause actual results to differ materially from those expressed by the company verbally and in writing today, including without limitation, risks and uncertainties related to product commercial success, market competition, regulatory review and approval processes, conducting clinical trials, compliance with applicable regulatory requirements, our dependence on collaboration partners and the level of costs associated with discovery, product development, business development and commercialization activities.